Singlomics
Harnessing single-cell sequencing to create advanced antibody therapies for infectious diseases and cancers
Harnessing single-cell sequencing to create advanced antibody therapies for infectious diseases and cancers
Singlomics, founded in 2020, is a biotechnology startup utilizing single-cell sequencing technology to develop advanced antibody therapies for infectious diseases and cancers. With the slogan "Harnessing single-cell sequencing to create advanced antibody therapies for infectious diseases and cancers," Singlomics aims to revolutionize the treatment landscape. In July 2023, the company secured a noteworthy CNY10.00M Venture Round investment, indicative of investor confidence in its innovative approach. Singlomics operates within the Biotechnology and Health Care industries, positioning itself at the intersection of cutting-edge technology and pressing medical needs.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | CNY10.00M | - | 01 Jul 2023 | |
| Venture Round | Unknown | 1 | Tencent | 03 Aug 2022 |
| Series B | CNY300.00M | 9 |
|
02 Feb 2022 |
| Series A | Unknown | - | 01 Dec 2020 | |
| Series A | CNY100.00M | - | 01 Sep 2020 |
We care about your data, and we'd love to use cookies make your experience better.
